Smoke-free products and their potential impact on COPD
In our eleventh Open Science event, we focus on the potential impact that smoke-free products can have on COPD, the third leading cause of death worldwide.
To do so, a panel composed of two leading scientists from PMI, a guest scientist from Swedish Match, and a professor of internal medicine review in detail the data available worldwide. Together, they have an open discussion on PMI's modeling used in a study aimed at assessing the potential impact of tobacco control and smoke-free products on smoking-related COPD mortality.
They also discuss how in Sweden, the data seem to suggest that COPD rates among Swedish men have been significantly reduced after the use of the oral smokeless tobacco product snus overtook cigarette smoking among men. They also dive into the promising results of the first independent studies on smoke-free product use among COPD patients.
As is the case with Open Science events, the panel answers questions live from the audience providing further insights into the application of the population health impact model for other countries as well as discussing the limitations of the model itself. Furthermore, they address the health risks associated with oral smokeless products, emphasizing the importance of quitting tobacco and nicotine altogether is the best choice for individuals dealing with COPD. Learn more about this topic by watching this Open Science event.